BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 221 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 0.69 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $271,313 | -11.0% | 38,321 | -11.5% | 0.16% | -8.8% |
| Q2 2023 | $304,677 | +32.5% | 43,278 | +57.0% | 0.18% | +43.7% |
| Q1 2023 | $229,942 | -26.1% | 27,571 | +1.8% | 0.13% | -22.2% |
| Q4 2022 | $310,947 | -1.0% | 27,086 | +8.7% | 0.16% | +29.6% |
| Q3 2022 | $314,000 | +20.8% | 24,920 | +1.5% | 0.12% | +30.2% |
| Q2 2022 | $260,000 | -50.9% | 24,556 | -24.5% | 0.10% | -59.5% |
| Q1 2022 | $529,000 | +17.3% | 32,542 | 0.0% | 0.24% | +39.4% |
| Q4 2021 | $451,000 | +11.6% | 32,542 | +15.8% | 0.17% | -4.5% |
| Q3 2021 | $404,000 | -16.7% | 28,090 | -8.4% | 0.18% | -10.6% |
| Q2 2021 | $485,000 | +35.1% | 30,669 | -13.2% | 0.20% | +30.9% |
| Q1 2021 | $359,000 | +38.6% | 35,331 | +1.8% | 0.15% | +42.1% |
| Q4 2020 | $259,000 | +4.9% | 34,707 | -51.7% | 0.11% | -17.7% |
| Q3 2020 | $247,000 | -36.5% | 71,844 | -12.0% | 0.13% | -29.3% |
| Q2 2020 | $389,000 | +60.7% | 81,644 | -32.6% | 0.18% | +84.0% |
| Q1 2020 | $242,000 | -49.5% | 121,058 | -12.7% | 0.10% | +28.2% |
| Q4 2019 | $479,000 | +123.8% | 138,719 | +86.1% | 0.08% | +81.4% |
| Q3 2019 | $214,000 | -28.2% | 74,533 | -5.3% | 0.04% | -31.7% |
| Q2 2019 | $298,000 | +16.9% | 78,684 | +151.6% | 0.06% | -88.4% |
| Q1 2019 | $255,000 | -10.5% | 31,277 | -11.4% | 0.54% | +1008.2% |
| Q4 2018 | $285,000 | -55.3% | 35,300 | -57.7% | 0.05% | -25.8% |
| Q3 2018 | $637,000 | -22.3% | 83,470 | -41.7% | 0.07% | -90.9% |
| Q2 2018 | $820,000 | +11.6% | 143,132 | -7.1% | 0.72% | +13.6% |
| Q1 2018 | $735,000 | +110.6% | 154,147 | +116.9% | 0.64% | +45.7% |
| Q4 2017 | $349,000 | +17.1% | 71,081 | +25.0% | 0.44% | +995.0% |
| Q3 2017 | $298,000 | +3.8% | 56,873 | +10.1% | 0.04% | -7.0% |
| Q2 2017 | $287,000 | -32.8% | 51,671 | +1.5% | 0.04% | -43.4% |
| Q1 2017 | $427,000 | +46.7% | 50,888 | +10.6% | 0.08% | -12.6% |
| Q4 2016 | $291,000 | -22.2% | 46,010 | -45.8% | 0.09% | -51.9% |
| Q3 2016 | $374,000 | +55.2% | 84,907 | 0.0% | 0.18% | +1.1% |
| Q2 2016 | $241,000 | +225.7% | 84,907 | +223.5% | 0.18% | +75.5% |
| Q1 2016 | $74,000 | – | 26,246 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Burrage Capital Management LLC | 864,916 | $13,674,000 | 13.71% |
| Sarissa Capital Management LP | 4,261,000 | $67,366,000 | 5.36% |
| ORACLE INVESTMENT MANAGEMENT INC | 1,920,733 | $30,367,000 | 4.18% |
| HealthCor Management, L.P. | 3,248,100 | $51,352,000 | 2.05% |
| Parkman Healthcare Partners LLC | 351,961 | $5,565,000 | 1.22% |
| Bain Capital Public Equity Management II, LLC | 1,560,730 | $24,675,000 | 1.06% |
| Baker Brothers Advisors | 12,710,818 | $200,958,000 | 0.88% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,835,000 | $44,821,000 | 0.80% |
| Biondo Investment Advisors, LLC | 265,840 | $4,203,000 | 0.72% |
| EAM Global Investors LLC | 157,065 | $2,483,000 | 0.69% |